Merck’s Ebola Vaccine Found to Protect Against Deadly Virus
This article is for subscribers only.
An experimental Ebola vaccine manufactured by Merck & Co. was found to be highly protective against the deadly virus, showing promise in the fight against future outbreaks after an earlier epidemic killed thousands and highlighted a shortage of weapons to battle the disease.
The vaccine was studied in a trial involving more than 11,000 people in Guinea. Of those who received the shot in a final-stage trial, no Ebola cases were recorded after a ten-day incubation period, according to a study published in the medical journal, the Lancet.